Provectus News Provectus Biopharmaceuticals to
Post# of 98051
Posted On: 06/12/2014 8:46:13 AM
Provectus News
Provectus Biopharmaceuticals to Discuss Outline of Phase 3 Clinical Trial Of PV-10 To Treat Melanoma on Conference Call
Thursday June 12, 2014
Management Will Also Discuss Access to ASCO-Presented Phase 2 Melanoma Data, Developments in Other Cancer Indications and in PH-10 Use
Call Scheduled for Thursday, June 19, 2014 at 4 pm Eastern Daylight Time
KNOXVILLE, Tenn.--(BUSINESS WIRE) June 3, 2014 --Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT, http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, announced today that it will hold a conference call on Thursday, June 19, 2014, at 4 pm Eastern Daylight Time.
Management will discuss the outline of the Company's proposed Phase 3 study of PV-10 in the treatment of melanoma, developments in the use of PV-10 in other cancer indications, as well as PH-10 and news regarding its use. Management will also discuss its potential plans to monetize its PV-10 and PH-10 assets with various contemplated license and co-development transactions.
In addition, summary data from the PV-10 Phase 2 melanoma study is expected to be available on clinicaltrials.gov prior to the conference call.
Conference Call Thursday, June 19, 2014, at 4 PM EDT
The management of Provectus Biopharmaceuticals, Inc. will host a conference call Thursday, June 19, 2014 at 4 PM Eastern. Those who wish to participate in the conference call may telephone 877-407-4019 from the U.S. International callers may telephone 201-689-8337 approximately 15 minutes before the call. A webcast will also be available at www.pvct.com.
A digital replay will be available by telephone approximately two hours after the completion of the call until August 19, 2014, and may be accessed by dialing 877-660-6853 from the U.S. or 201-612-7415 for International callers, and using the Conference ID#13584727.
The complete press release is available at www.pvct.com/pressrelease.html?article=20140612 on the Provectus website.
Provectus Biopharmaceuticals to Discuss Outline of Phase 3 Clinical Trial Of PV-10 To Treat Melanoma on Conference Call
Thursday June 12, 2014
Management Will Also Discuss Access to ASCO-Presented Phase 2 Melanoma Data, Developments in Other Cancer Indications and in PH-10 Use
Call Scheduled for Thursday, June 19, 2014 at 4 pm Eastern Daylight Time
KNOXVILLE, Tenn.--(BUSINESS WIRE) June 3, 2014 --Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT, http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, announced today that it will hold a conference call on Thursday, June 19, 2014, at 4 pm Eastern Daylight Time.
Management will discuss the outline of the Company's proposed Phase 3 study of PV-10 in the treatment of melanoma, developments in the use of PV-10 in other cancer indications, as well as PH-10 and news regarding its use. Management will also discuss its potential plans to monetize its PV-10 and PH-10 assets with various contemplated license and co-development transactions.
In addition, summary data from the PV-10 Phase 2 melanoma study is expected to be available on clinicaltrials.gov prior to the conference call.
Conference Call Thursday, June 19, 2014, at 4 PM EDT
The management of Provectus Biopharmaceuticals, Inc. will host a conference call Thursday, June 19, 2014 at 4 PM Eastern. Those who wish to participate in the conference call may telephone 877-407-4019 from the U.S. International callers may telephone 201-689-8337 approximately 15 minutes before the call. A webcast will also be available at www.pvct.com.
A digital replay will be available by telephone approximately two hours after the completion of the call until August 19, 2014, and may be accessed by dialing 877-660-6853 from the U.S. or 201-612-7415 for International callers, and using the Conference ID#13584727.
The complete press release is available at www.pvct.com/pressrelease.html?article=20140612 on the Provectus website.
(0)
(0)
I'm in it to win it!
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
Scroll down for more posts ▼